AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01728558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care sedation
Study NCT01231542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
Study NCT01231542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin is approved by the FDA for the treatment of tuberculosis.
Study NCT01231542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin is approved by the FDA for the treatment of tuberculosis.
Study NCT00607269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher-Based Reinforcement Therapy
Description: Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).~Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol \<0.05) urine sample.
Study NCT00098748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Therapy (OBT)
Description: OBT (3-6 drugs based on treatment history and resistance testing)
Study NCT00098748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc (UK-427,857)
Description: maraviroc (UK-427,857) 150 mg taken once daily
Study NCT00098748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc (UK-427,857)
Description: maraviroc (UK-427,857) 150 mg taken twice daily
Study NCT02975479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALK Diluent
Study NCT02975479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Alutard SQ 5-grasses or ALK Alutard Birch
Description: Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
Study NCT03305081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD, copper IUD, etonorgestrel implant
Description: Long-acting reversible contraception
Study NCT03305081 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUD, copper IUD, etonorgestrel implant
Description: Long-acting reversible contraception
Study NCT03955250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile After-Care Support (MACS) app
Description: The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning.
Study NCT03955250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile app attention control
Description: The control app provides ecological momentary assessment and psychoeducation about illness.
Study NCT01349777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix®
Description: Plavix® 75mg daily for 12 months
Study NCT02969265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine Capsules
Study NCT02969265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCV-116CCB
Description: TCV-116CCB Tablets
Study NCT02969265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Placebo
Description: Amlodipine placebo-matching capsules
Study NCT02969265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCV-116CCB Placebo
Description: TCV-116CCB 8/5 mg placebo-matching tablets
Study NCT04389892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast enhanced harmonic endoscopic ultrasound
Description: During the echoendoscopy the image was fixed on the region of interest (pancreatic cyst) and the extended pure harmonic detection mode was selected. 2,4ml contrast enhancement (Sonovue-Bracco Italy) was injected in the right antecubital vein of the participants followed by a flush of 5ml 0.9% saline solution to ensure that the entire quantity of the agent goes in to the blood flow.~After the administration the pancreatic cyst was observed for at least 120 seconds.We followed the enhancing behavior of the cyst wall, the septa and the solid components. Arterial enhancement (contrast uptake) was considered the first 25-30 seconds after injection and the venous phase (wah-out) 30-45 seconds after injection.~EUS-FNA was performed in all patients without contraindications
Study NCT01683409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT04218084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: Participants are randomized 1:1 to receive voxelotor or placebo.
Study NCT04218084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study NCT01506167 — intervention group
Intervention type: DRUG
Intervention: Capecitabine/Oxaliplatin
Description: Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Study NCT01506167 — intervention group
Intervention type: DRUG
Intervention: Fluorouracil/Folinic Acid/Oxaliplatin
Description: Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Study NCT01506167 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine was administered along with bevacizumab as part of standard first-line treatment
Study NCT01506167 — intervention group
Intervention type: DRUG
Intervention: Fluorouracil/Folinic Acid/Irinotecan
Description: Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
Study NCT01506167 — intervention group
Intervention type: DRUG
Intervention: Fluorouracil +/- Folinic Acid
Description: Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
Study NCT01868750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: 1.0ug twice daily for 7 days before surgery
Study NCT01868750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Pill
Description: placebo pill taken twice daily for 7 days before surgery
Study NCT02632955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon
Description: After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
Study NCT02632955 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Regular angioplasty
Description: After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
Study NCT00144963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposomes Injection
Description: Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
Study NCT00144963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
Study NCT02536040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% diammine silver fluoride
Description: treatment of cavity with study agent
Study NCT02536040 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Fluoride free, distilled water
Study NCT01683409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT01683409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01860079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early discharge
Description: In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
Study NCT03766009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT03766009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care
Study NCT03766009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Description: Web-based decision aid received prior to the surgical consultation
Study NCT02684630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel System
Description: Platelet Apheresis Procedure
Study NCT02699060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy with biopsy and collection of refluxate
Description: we analyzed esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects, as well as the appearance of the gastric and duodenal mucosa.
Study NCT02699060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring
Description: we analyzed following HRM parameters: the distal contractile integral (DCI), the lower esophageal sphincter resting pressure (LES RP) and standard measuring parameters were be collected: percentage of total time when pH was \<4, longest reflux event, number of reflux events longer than 5 minutes, and number of reflux episodes in 24 hours.
Study NCT00770081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: 50mg qd
Study NCT00770081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: 25mg qd
Study NCT01279083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-112
Description: Topical ocular solution
Study NCT03742102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Study NCT03742102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
Study NCT03742102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
Study NCT03742102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
Study NCT01279083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DE-112 Vehicle Solution
Description: Topical ocular solution
Study NCT01279083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Solution
Description: Topical ocular solution
Study NCT02283008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of inhaler technique pre and 6 weeks post training
Description: Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
Study NCT03813953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection
Description: Resection of diseased liver
Study NCT03813953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection
Description: Resection of diseased liver
Study NCT01758588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 50 mcg subcutaneous injection once per week
Study NCT00767624 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antidepressant
Description: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Study NCT00767624 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Desensitization Therapy for Insomnia
Study NCT00767624 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy for Insomnia
Study NCT02826538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fracture fixation with patient specific guides
Description: Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation
Study NCT02826538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard procedure of fracture fixation
Description: the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
Study NCT01734200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eriobotyra Japonica Lindley Extract
Description: Eriobotyra Japonica Lindley Extract (1.5g/day)
Study NCT01734200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1.5g/day)
Study NCT00381160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction of sugar-sweetened beverage consumption
Description: Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
Study NCT04790708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lutetium-177 (177Lu)-DOTATOC
Description: 5 cycles of 3,7 e 5,55 gigabequerel (GBq) of 177Lu-DOTATOC every 8-10 weeks. Cumulative activity: 18,5 e 27,75 GBq
Study NCT04790708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (90Y)-DOTATOC
Description: 5 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks. Cumulative activity: 9,25 e 13,875 GBq
Study NCT04790708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC + 90Y-DOTATOC
Description: 3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC alternated with 2 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks.~Cumulative activity: 18,5 e 27,75 GBq of 177Lu-DOTATOC and 9,25 e 13,875 GBq of 90Y-DOTATOC
Study NCT04790708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-treatment 177Lu-DOTATOC
Description: 3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC every 8-10weeks. Cumulative activity: 11,1 e 16,65 GBq of 177Lu-DOTATOC
Study NCT03632525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Single dose of 20 mg/kg ferric carboxymaltose (maximum 1000 mg for patients with haemoglobin \<14 g/dL or 500 mg for patients with haemoglobin ≥14 g/dL).
Study NCT04790708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-treatment 90Y-DOTATOC
Description: 3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC
Study NCT04482673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily Vitamin D3
Description: 6000 IU vitamin D3 daily
Study NCT04482673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daily placebo
Description: Placebo daily
Study NCT04482673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus vitamin D3
Description: Bolus 20,000 IU vitamin D3 daily for 3 days
Study NCT04482673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bolus placebo
Description: Bolus placebo daily for 3 days
Study NCT01366690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: A trained peer supporter is assigned to support newly HIV-positive diagnosed persons.
Study NCT03742102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
Study NCT03742102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
Study NCT03278782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03278782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV
Study NCT02145832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Study NCT01326650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: daily oral vitamin D supplement of 100 micrograms for three years
Study NCT02145832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Study NCT01326650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily oral placebo supplement for three years
Study NCT03909880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Kinesio tape (kinesio taping; kinesio holding corporation,USA) was placed on the skin above muscle belly of finger flexor. There were three types of taping:~Taping20 condition - tape was pulled from the wrist to the proximal forearm. The two ends of the tape (\~5 cm) were held by the therapist and the middle area was pulled 20% additional tension.~TapingN condition - tape was pulled with neutral tension. Control condition - no taping.
Study NCT03909880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio tape
Description: Kinesio tape (kinesio taping; kinesio holding corporation,USA) was placed on the skin above muscle belly of finger flexor. There were three types of taping:~Taping20 condition - tape was pulled from the wrist to the proximal forearm. The two ends of the tape (\~5 cm) were held by the therapist and the middle area was pulled 20% additional tension.~TapingN condition - tape was pulled with neutral tension. Control condition - no taping.
Study NCT01446328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: Tablets, dose range 50-1200 mg/ day
Study NCT01446328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, dose range 5-30 mg/ day
Study NCT01446328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Tablets, dose range 2.5-20 mg/ day
Study NCT01767948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
Study NCT04634682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MYODM
Description: Formulated composition containing Theobroma cacao supplemented with caffeine
Study NCT01088841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lactisole
Description: lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
Study NCT01088841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactisole
Description: lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
Study NCT03000257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet taken orally
Study NCT03000257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab Tesirine
Description: Intravenous infusion
Study NCT03000257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous infusion
Study NCT04068506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg Tab
Description: Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
Study NCT04068506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 600 mg Tab
Description: Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT06549712 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: identify genetic determinants of the predisposition to develop respiratory failure
Description: To identify the main common genetic determinants of severe COVID-19 by conducting a GWAS: in first phase we will compare SARS-CoV-2 positive patients with severe lung affection to healthy controls from the same geographic area, in order to provide initial data informing the research in the field in a timely fashion. This will be conducted in close collaboration with the University of Kiel COVID-19 genomic initiative. Later on, we will proceed to assess objectives 1 and 2 in the full cohort, including also infected controls who did not developed clinically significant symptoms